GLOBAL STATUS OF THE PROBLEMS OF DIFFERENTIAL DIAGNOSIS OF MELANOMA AMONG PATIENTS WITH MELANOCYTIC LESIONS AND NEOPLASMS

Authors

  • POLATOVA Jamilya Shagayratovna
  • TAGAEV Jasur Abdisamatovich

Keywords:

дифференциальная диагностика меланомы, меланоцитарные новообразования, фотодерматоскопия, иммуногистохимия

Abstract

Objective: The purpose of the study is to assess the state of modern methods and trends in the complex differential diagnosis of melanoma among patients with melanocytic neoplasms based on a systematic analysis of the scientific literature.

Conclusions: The issue of early differential diagnosis of oncological diseases plays an important role in the framework of modern effective care for oncological patients. As for melanoma itself, which occurs in millions of people around the world and has a clear upward trend in incidence, it is a serious medical and social problem. The solution to this issue involves taking into account many factors, the combination of which may lead to some success in the treatment of melanoma, which will ultimately lead to a decrease in disability and mortality in patients

References

Malik S, Dixit VV. “Skin cancer detection: state of art methods and challenges,” ICCCE, vol. 2021, pp. 729–736, 2022.

L. Rey-Barroso, S. Pena-Guti´errez, C. Y´anez, F. J. Burgos Fernandez, M. Vilaseca, and S. Royo, “Optical technologies for the improvement of skin cancer diagnosis: a review,” Sensors, vol. 21, no. 1, p. 252, 2021.

Шулаев А.В., Зарипова Р.Н., Жабоева С.Л. Распространенность факторов риска рака кожи и управление ими. // Общественное здоровье и здравоохранение. 2020. №2 (66).

Smith RA, Andrews KS, Brooks D, Fedewa SA, Manassaram-Baptiste D, Saslow D, Brawley OW, Wender RC. Cancer screening in the United States, 2018: A review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin. 2018 Jul;68(4):297-316. doi: 10.3322/caac.21446. Epub 2018 May 30. PMID: 29846940.

Tillyashaykhov M.N., Djanklich S.M., Ibragimov S.N., Imamov O.A. Analysis of cancer incidence structure in the Republic of Uzbekistan. Онкология и радиология Казахстана, 2021, 61(3)4-8.

Narayanan DL, Saladi RN, Fox JL. Ultraviolet radiation and skin cancer. Int J Dermatol 2010;49:978-986

Maden V, Leah JT, Szeimies RM. Non-melanoma skin cancer. Lancet 2010;375:673-685.

Brenner M, Hearing VL. The protective role of melanin against UV damage in human skin. Photochem Photobiol 2007;84:539-549.

Benjamin CL, Ananthaswamy HN. The pathogenesis of skin cancer. Toxicol Appl Pharmacol 2007;224: 241-248.

Owida HA. Developments and Clinical Applications of Noninvasive Optical Technologies for Skin Cancer Diagnosis. J Skin Cancer. 2022 Nov 18;2022:9218847.

Elder DE. Precursors to melanoma and their mimics: nevi of special sites. Mod Pathol 2006;19:S4–S20.

Bandyopadhyay D. Halo nevus. Indian Pediatr 2014; 51: 850.

Fernandez-Flores A. Eponyms, Morphology, and Pathogenesis of some less mentioned types of melanocytic nevi. Am J Dermatopathol 2012; 34: 607–18.

Stolz W, Bilek P, Landthaler M, et al. Skin surface microscopy. Lancet 1989; 334: 864-5.

Braun RP, Rabinovitz HS, Oliviero M, et al. Dermoscopy of pigmented skin lesions. J Am Acad Dermatol 2005; 52: 109-21.

Vestergaard ME, Macaskill P, Holt PE, Menzies SW. Dermoscopy compared with naked eye examination for the diagnosis of primary melanoma: a meta-analysis of studies performed in a clinical setting. Br J Dermatol 2008; 159: 669-76.

Sheu SL, Cho HG, Nord KM. Videodermoscopy as a novel tool for dermatologic education. Cutis 2017; 100: E25-7.

Russo T, Piccolo V, Ferrara G, et al. Dermoscopy pathologycorrelation in melanoma. J Dermatol 2017; 44: 507-14.

Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg. 1970 Nov;172(5):902-8. doi: 10.1097/00000658-197011000-00017. PMID: 5477666; PMCID: PMC1397358.

Keung EZ, Gershenwald JE. The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care. Expert Rev Anticancer Ther. 2018 Aug;18(8):775-784.

Fleming MD, Galan A, Gastman B, et al. Aim at Melanoma NCCN Guidelines Version 3.2018 Melanoma.; 2018

Koseła H, Świtaj T, Rutkowski P, et al. Przypadki kliniczne chorych na zaawansowane czerniaki leczonych ipilimumabem. Onkol Prakt Klin 2015; 11: A1-8.

Scolyer RA, Jackett LA. Review of Key Biological and Molecular Events Underpinning Transformation of Melanocytes to Primary and Metastatic Melanoma. Cancers 2019, 11, 2041

Zeng H, MacAulay C, McLean D, Palcic B. Spectroscopic and microscopic characterization of human skin autofluorescence emission. Photochem. Photobiol. 1995, 61, 639–645.

Gallas JM, Eisner M. Fluorescence of melanin–dependence upon excitation wavelenght and concentration. Photochem. Photobiol. 1987, 45, 595–600.

Teuchner K, Ehlert J, Freyer W, Leupold D, Altmeyer P, Stücker M, Hoffmann K. Fluorescence studies by stepwise two-photon laser excitation. J. Fluoresc. 2000, 20, 275–281.

Leupold D, Pfeifer L, Hofmann M, Forschner A, Wessler G, Haenssle H. From Melanocytes to Melanoma Cells: Characterization of the Malignant Transformation by Four Distinctly Different Melanin Fluorescence Spectra (Review). Int J Mol Sci. 2021 May 17;22(10):5265.

de la Fouchardiere A, Blokx W, van Kempen LC, Luzar B, Piperno-Neumann S, Puig S, et al. Esp, EORTC, and EURACAN Expert Opinion: Practical Recommendations for the Pathological Diagnosis and Clinical Management of Intermediate Melanocytic Tumors and Rare Melanoma Variants. VirchArch (2021).

Long GV, Wilmott JS, Capper D, Preusser M, Zhang YE, Thompson JF, et al. Immunohistochemistry is Highly Sensitive and Specific for the Detection of V600E BRAF Mutation in Melanoma. Am J Surg Pathol (2013) 37:61–5.

Zhang AJ, Rush PS, Tsao H. Duncan LM BRCA1-Associated Protein (BAP1)-Inactivated Melanocytic Tumors. J Cutan Pathol (2019)

Ferrara G, Mariani MP, Auriemma M. BAP1-Inactivated Melanocytic Tumour With Borderline Histopathological Features (BAP1-Inactivated Melanocytoma): A Case Report and a Reappraisal. Australas J Dermatol (2021) 62:e88–91.

Lezcano C, Jungbluth AA, Nehal KS, Hollman TJ. PRAME Expression in Melanocytic Tumors. Busam KJ Am J Surg Pathol (2018) 42:1456–65.

Kiuru M, Jungbluth A, Kutzner H, Wiesner T, Busam KJ. Spitz Tumors: Comparison of Histological Features in Relationship to Immunohistochemical Staining for ALK and NTRK1. Int J Surg Pathol (2016) 24:200–6.

Quan VL, Panah E, Zhang B, Shi K, Mohan LS, Gerami P. The Role of Gene Fusions in Melanocytic Neplasms. J Cutan Pathol (2019) 46:878–87.

DePalo DK, Zager JS. Advances in Intralesional Therapy for Locoregionally Advanced and Metastatic Melanoma: Five Years of Progress. Cancers (Basel). 2023 Feb 23;15(5):1404.

Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677-704.

Rizaev J.A, Rahimov N.M., Kadirov X.X., Shaxanova Sh.Sh. (2023). Oncoepidemiological assessment of the incidence and mortality of prostate cancer for the period 2015-2020 in the cross section of the republic of uzbekistan and individual regions. Open Access Repository, 4(3), 1108–1113. https://doi.org/10.17605/OSF.IO/J3KWB

Maksudov Dilshod D., Musurmanov Fazliddin I. et al. "Development of a Comprehensive Programme for the Comprehensive Treatment of Patients with Maxillofacial Phlegmon with Viral Hepatitis B." JournalNX, vol. 7, no. 02, 2021, pp. 191-198.

Rakhimov M. Nodir, Khudayberdiyeva A. Shohista, Oripova R. Mehriniso, Shakhanova Sh. Shakhnoza. Practical recommendations forNutritional support for cervical cancer// Journal of Biomedicine and Practice. 2023, vol. 8, issue 2,pp.224-230

Shakhanova Sh. Shakhnoza, Rakhimov M. Nodir. Aspects of sarcopenia syndrome in oncological practice: diagnosis and treatment (literature review) // Journal of Biomedicine and Practice. 2023, vol. 8, issue 3, pp. 406-417

Buchbinder EI, Desai A. CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition. Am J Clin Oncol. 2016 Feb;39(1):98-106.

Ascierto PA, Ferrucci PF, Fisher R, Del Vecchio M, Atkinson V, Schmidt H, et al. Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma. Nat Med 2019;25(6):941–6.

Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, Dummer R, Trefzer U, Larkin JM, Utikal J, Dreno B, Nyakas M, Middleton MR, Becker JC, Casey M, Sherman LJ, Wu FS, Ouellet D, Martin AM, Patel K, Schadendorf D; METRIC Study Group. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012 Jul 12;367(2):107-14.

Published

2023-10-31